2025-12-17 浙江大学(ZJU)
<関連情報>
- https://www.zju.edu.cn/english/2025/1217/c19573a3120383/page.psp
- https://www.sciencedirect.com/science/article/abs/pii/S009286742501311X
標的薬物送達と増強癌免疫療法のための感作肥満細胞 Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy
Yan Xu, Xiaoge Zhang, Xiao Han, Hanwei Huang, Chaoyang Meng, Yinxian Yang, Tao Sheng, En Ren, Jiaqi Shi, Kaixin He, Dong Cen, Peng Zhao, Weijia Fang, Hongjun Li, Yuqi Zhang, Xiujun Cai, Funan Liu, Jicheng Yu, Zhen Gu
Cell Available online: 9 December 2025
DOI:https://doi.org/10.1016/j.cell.2025.11.015
Graphical abstract
Highlights
- IgE-MCs serve as drug delivery carriers for targeting antigen-positive tumors
- Modular platform supports patient-specific IgE selection and diverse payloads
- Antigen binding activates IgE-MCs to release oncolytic viruses and cytokines/chemokines
- IgE-MCs reverse immunosuppression and activate antitumor immunity
Summary
Cell-mediated drug-delivery systems have garnered significant attention for their potential to boost therapeutic efficacy in cancer treatment. Here, we engineered immunoglobulin E (IgE)-sensitized mast cells (IgE-MCs) to achieve antigen-guided delivery of oncolytic adenoviruses (OVs) and local immune activation. By harnessing tumor-specific antigens as allergens, IgE-MCs accumulated at antigen-positive tumors, enabling targeted OV delivery and releasing chemokines and inflammatory mediators that remodeled the tumor microenvironment. IgE-MCs encapsulating OVs induced robust anticancer immune responses and inhibited tumor growth in several murine models. Of note, in a humanized human epidermal growth factor receptor-2 (HER2)-positive patient-derived xenograft model, human MCs armed with anti-HER2 IgE and loaded with OVs increased intratumoral T cell responses and reduced tumor growth, demonstrating feasibility in a clinically relevant setting and supporting patient-specific IgE selection. Together, our study highlights the translational promise of IgE-MCs as an antigen-specific delivery platform for cancer immunotherapy.
